Atea Pharmaceuticals (AVIR) vs ARS Pharmaceuticals (SPRY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Atea Pharmaceuticals (AVIR) has outperformed ARS Pharmaceuticals (SPRY) over the past year, gaining 68.7% versus a loss of 57.8%. Over five years, SPRY leads with a -55.8% price change compared with -87.2% for AVIR. ARS Pharmaceuticals is the larger company by market cap ($428.6 million vs $403.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVIR | SPRY |
|---|---|---|
| Share price | $5.03 | $4.31 |
| Market cap | $403.43M | $428.62M |
| 1-day change | +0.40% | -1.15% |
| YTD return | +40.34% | -62.58% |
| 1-year return | +68.69% | -57.79% |
| 5-year return | -87.25% | -55.78% |
| EPS (TTM) | $-2.09 | $-2.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.45 | $13.15 |
| 52-week low | $2.87 | $3.99 |
| Distance from 52-week high | -22.02% | -67.22% |
| Analyst consensus | none | none |
| Avg. price target upside | +87.28% | +422.04% |
| Average volume | 298.38K | 1.85M |
| Shares outstanding | 80.20M | 99.45M |
| Employees | 55 | 195 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVIR has outperformed SPRY by 126.5 percentage points over the past year.
About Atea Pharmaceuticals
AVIR stock →Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About ARS Pharmaceuticals
SPRY stock →ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.
Health Care · Biotechnology: Pharmaceutical Preparations · 195 employees
AVIR vs SPRY FAQ
Which is bigger, Atea Pharmaceuticals or ARS Pharmaceuticals?
ARS Pharmaceuticals (SPRY) is larger, with a market capitalization of $428.62M compared with $403.43M for Atea Pharmaceuticals (AVIR).
Which stock has performed better over the past year, AVIR or SPRY?
AVIR returned +68.69% over the past 12 months, compared with -57.79% for SPRY (price return, excluding dividends). Past performance does not predict future results.
Are Atea Pharmaceuticals and ARS Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.